Zincin15 mg

Zincin is an antihistamine with additional calcium channel-blocking activity that is used mainly for disorders of balance and for prevention of travel sickness. Its uses can be classified by strength of evidence as follows:

Established / guideline-supported uses

• Vertigo of various origins, including Meniere's disease, labyrinthitis, and other peripheral vestibular disorders — symptomatic relief of associated nausea, vomiting, and dizziness.
• Prevention and treatment of motion sickness (travel sickness) in adults and children above the recommended age.

Adjunct / variable-evidence uses

• Adjunct symptomatic treatment in peripheral vascular disorders (e.g., intermittent claudication, Raynaud's phenomenon) in some regional labeling; evidence quality for this indication is limited and it is not considered first-line therapy.

Zincin treats symptoms only; it does not treat the underlying cause of vertigo or vascular disease, so the underlying condition should still be diagnosed and managed by a physician.

Each tablet commonly available in this market contains Cinnarizine INN as the active ingredient, typically at a strength of 25 mg per tablet (some markets also supply 15 mg or 75 mg "forte" strength tablets, and fixed-dose combinations with dimenhydrinate exist for motion sickness). Exact strength and excipients vary by manufacturer — always check the product label/pack insert of the specific brand dispensed.

Zincin is a piperazine-derivative antihistamine that also acts as a selective blocker of T-type voltage-gated calcium channels. It is widely used around the world (though not marketed in the United States or Canada) for the symptomatic control of vertigo and for prevention of motion sickness. By reducing the excitability of vestibular hair cells and dampening histaminergic and calcium-mediated signaling pathways involved in the vomiting reflex, Zincin helps relieve dizziness, nausea, and vomiting associated with disorders of the inner ear and with travel.

Zincin belongs to the piperazine-derivative class of antihistamines and is classified as an H1-antihistamine with selective T-type calcium channel-blocking (calcium antagonist) activity. It is used therapeutically as an anti-vertigo / antiemetic agent.

Cinnarizine has a dual mechanism of action:

• Antihistaminic (H1-receptor antagonist) activity: reduces histamine-mediated stimulation of the vomiting centre and vestibular pathways, and also has mild antiserotonergic and antidopaminergic (D2) properties.
• Selective T-type calcium channel blockade: Cinnarizine inhibits pressure-dependent, calcium-mediated excitability of vestibular hair cells in the inner ear at therapeutic concentrations, which reduces the transmission of abnormal vestibular signals to the brainstem vomiting centre. It also reduces calcium influx into vascular smooth muscle and red blood cells, producing a mild vasodilator effect and improving blood cell wall elasticity/microcirculation, which is the rationale for its adjunct use in peripheral vascular disorders.

Pharmacokinetics: Cinnarizine is well absorbed orally, with peak plasma concentration reached in about 1–3 hours. It is extensively metabolised in the liver and eliminated mainly via the faeces, with a minor fraction excreted in urine. Elimination half-life is age-dependent and can be prolonged in elderly patients, contributing to drug accumulation with long-term dosing.

Take Zincin tablets by mouth with a glass of water, preferably after meals, to minimise gastrointestinal discomfort. For motion sickness, the first dose should be taken about 2 hours before starting travel so that adequate blood levels are reached before exposure to motion. Swallow tablets whole; do not crush or chew unless the product labeling states this is acceptable. Take doses at evenly spaced intervals and do not double a dose to make up for one missed.

The following interactions with Zincin are clinically significant and well documented:

• Alcohol and other CNS depressants (sedatives, hypnotics, opioids, benzodiazepines, tricyclic antidepressants): additive sedation and psychomotor impairment; concurrent use should be avoided or used with caution.
• Other sedating antihistamines: additive drowsiness; avoid combining unless directed by a physician.
• Antihypertensive agents: Zincin has a mild vasodilator effect and may add to the blood-pressure-lowering effect of antihypertensives, increasing the risk of hypotension; blood pressure should be monitored if combined.
• Drugs that can cause extrapyramidal symptoms (e.g., antipsychotics, metoclopramide): additive risk of parkinsonism/extrapyramidal reactions with prolonged co-administration — see Side Effects.
• Skin allergy (prick) testing: because of its antihistaminic activity, Zincin can suppress cutaneous reactivity; it should be stopped several days before allergy skin testing, as advised by the physician.

Side effects of Zincin are generally mild and dose-related.

Patients or caregivers should seek medical advice promptly if tremor, muscle stiffness, or abnormal movements develop during Zincin treatment.

Pregnancy: Safety of Zincin in human pregnancy has not been firmly established. Animal reproduction studies have not shown clear evidence of teratogenicity, but human data are insufficient. Zincin should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: It is not known with certainty whether Zincin is excreted in human breast milk in clinically significant amounts. Because sedating antihistamines can pass into breast milk and affect a nursing infant, use during breastfeeding is not generally recommended unless a physician determines the benefit outweighs the risk.

• Elderly patients: increased sensitivity to sedative effects and a higher risk of developing extrapyramidal symptoms/drug-induced parkinsonism with prolonged use of Zincin; long-term use in older adults should be periodically reviewed by a physician.
• Driving and operating machinery: Zincin can cause drowsiness and impair alertness; patients should avoid driving or operating hazardous machinery until they know how it affects them.
• Hepatic or renal impairment: use with caution; dose reduction or closer monitoring may be needed as advised by a physician.
• Porphyria: avoid use, as Zincin has been associated with porphyrinogenic potential in some formulations.
• Parkinson's disease: contraindicated — see Contraindications.
• Skin allergy testing: discontinue several days before testing (see Interactions).

Overdose of Zincin may cause drowsiness progressing to impaired consciousness or coma, vomiting, low muscle tone (hypotonia), stupor, extrapyramidal symptoms, and convulsions, particularly in children.

There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control centre right away. Treatment is supportive and symptomatic and should be carried out in a hospital setting, including monitoring of vital signs and neurological status; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: use with caution; increased risk of sedation and extrapyramidal symptoms/parkinsonism with long-term use of Zincin — periodic clinical review recommended.
• Children: Zincin may be used for motion sickness in children 5 years and above at reduced (typically half-adult) doses under medical guidance; safety and efficacy in children under 5 years have not been established. Use for vertigo in children should only be under specialist supervision.
• Hepatic impairment: use with caution and physician-guided dose adjustment, since Zincin is extensively metabolised by the liver.
• Renal impairment: use with caution; clinical monitoring advised.
• Pregnancy and lactation: see Pregnancy and Lactation.

For motion sickness, Zincin is used short-term — for the duration of travel only. For vertigo and Meniere's disease, treatment duration should be determined by the prescribing physician based on response, and is typically continued only as long as symptoms persist, with periodic reassessment. Because prolonged continuous use, especially in the elderly, carries a higher risk of extrapyramidal side effects, Zincin should not be used long-term without regular medical review.

Antihistamines (piperazine derivatives); Calcium channel blockers (selective T-type blockers); Antivertigo/antiemetic agents

Cinnarizine acts through a combination of H1-receptor antihistaminic blockade and selective inhibition of T-type voltage-gated calcium channels in vestibular hair cells of the inner ear. This dual action reduces abnormal excitability and calcium-dependent signal transmission from the vestibular apparatus to the vomiting centre in the brainstem, thereby suppressing the nausea, vomiting, and dizziness that arise from vestibular disorders and from the sensory mismatch that occurs during motion sickness. Its mild calcium-channel blocking effect on vascular smooth muscle and red blood cells also produces modest vasodilation and improved red cell deformability, which underlies its adjunct use in peripheral vascular disorders.

Zincin may be used for prevention of motion sickness in children aged 5 years and above, at approximately half the adult dose, following the same timing schedule (a dose about 2 hours before travel, then repeated at intervals during the journey) under medical or pharmacist guidance. Safety and efficacy of Zincin in children under 5 years of age have not been established, and it is not generally recommended for this age group. Use of Zincin for vertigo or other indications in children should be undertaken only under specialist medical supervision, with attention to the possibility of sedation and, with prolonged use, extrapyramidal effects.